Relmada Therapeutics CMO Raj S. Pruthi Purchases 55,000 Shares In Open Market On August 29, 2025
Benzinga Newsdesk 1 year ago
NewsInsider Trades
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per
On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share.